Clinical trials: Marijuana
RETT Syndrome With Proven MECP2 Mutation, Rett Syndrome
Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome
The FENRTT2 study will investigate the efficacy and safety of a medicinal cannabis plant extract with extremely low THC (delta-9-tetrahydrocannabinol), NTI164, on Rett syndrome (RTT) in a crossover design.
- Trial name
- TRANSCEND (NCT07257978)
- Testing
- NTI164
- Where
- Australia
- Volunteers
- 40 people
- Sponsor
- Fenix Innovation Group
Substance-related Disorders, Alcohol-Related Disorders
LaunchPad: Supporting Healthy Decisions and Preventing Drug Use After High School
LaunchPad is an online substance use prevention program for high school seniors. The program is designed to help seniors develop skills and make informed decisions as they transition from high school to young adulthood.
- Conditions
- Substance-related Disorders, Alcohol-Related Disorders, Tobacco Use Disorder, Marijuana Use
- Trial name
- NCT07655609
- Testing
- Introduction, Norms re: Protective Behavior Strategies (PBS), Life Skills
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Prevention Strategies, LLC
Rett Syndrome
Assessing the Safety and Efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) in the Treatment of Rett Syndrome (RTT)
This 18-week open-label study examines the effectiveness of Full-Spectrum Medicinal Cannabis Plant Extract containing 0.08% THC (NTI164) in treating Rett syndrome (RTT) in children and young people.
- Trial name
- NCT06621043
- Testing
- NTI164
- Where
- Australia
- Volunteers
- 14 people
- Sponsor
- Fenix Innovation Group
Adolescent Drinking, Adolescent Problem Behavior
Mindfulness Mobile App to Reduce Adolescent Substance Use
Substance-abusing youth - especially those who are involved in the juvenile justice system - are at higher risk than nonusers for mental health problems, including depression, conduct problems, personality disorders, suicidal…
- Trial name
- Qlarity (NCT04027075)
- Testing
- Qlarity app users
- Where
- United States
- Volunteers
- 257 people, healthy volunteers welcome
- Sponsor
- Oregon Research Behavioral Intervention Strategies, Inc.
Autism, Autism Spectrum Disorder
NTI164 in Autism Spectrum Disorder
This is a double-blind, randomised, placebo-controlled study investigating the efficacy of a full-spectrum medicinal cannabis plant extract on core and associated ASD symptoms over placebo.
- Conditions
- Autism, Autism Spectrum Disorder, Autism Disorder
- Trial name
- Beyond Harmony (NCT07257939)
- Testing
- NTI164
- Where
- 3 sites in Australia
- Volunteers
- 200 people
- Sponsor
- Fenix Innovation Group
Autism, Autism Spectrum Disorder
Placebo-Controlled Study of Terpenes-Enriched Cannabis Oil T1/C28 for Children With Autism
The goal of this clinical trial is to determine whether cannabidiol (CBD, 28%) combined with terpenes and a small amount of THC (1%) can help reduce symptoms of autism, and to evaluate the safety of this treatment.
- Trial name
- TECA (NCT07199218)
- Testing
- Terpenes-Enriched CBD-Predominant Oil, Terpenes-Enriched CBD Oil (THC-Free)
- Where
- Israel
- Volunteers
- 78 people
- Sponsor
- Bazelet Nehushtan LtD.
Cerebral Palsy
A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 Years
A study to assess the effects of Sativex treatment on spasticity in a population of children and adolescents aged from 8 to 18 years with cerebral palsy or traumatic central nervous system injury.
- Trial name
- NCT01898520
- Testing
- Sativex
- Where
- 14 sites in Czechia, Israel and 1 more
- Volunteers
- 72 people
- Sponsor
- Jazz Pharmaceuticals
Attention Deficit Hyperactivity Disorder, Cannabis Abuse
Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE
The purpose of this study is to determine whether atomoxetine is effective in reducing ADHD (Attention Deficit/Hyperactivity Disorder) symptoms in adolescents with ADHD and comorbid cannabis abuse.
- Trial name
- PEACE (NCT00687609)
- Testing
- Atomoxetine
- Where
- Netherlands
- Volunteers
- 7 people
- Sponsor
- Eli Lilly and Company
Multiple Sclerosis, Diabetes
An Observational Post-Marketing Safety Registry of Sativex®
The purpose of this registry is to monitor safety outcomes of patients who are receiving Sativex® for Multiple Sclerosis (MS) spasticity and for off-label indications in the United Kingdom (UK), Germany and Sweden.
- Conditions
- Multiple Sclerosis, Diabetes, Cancer, Neuropathic Pain
- Trial name
- NCT02073474
- Testing
- Sativex®
- Volunteers
- 978 people
- Sponsor
- Jazz Pharmaceuticals
Acute Cannabis-induced CNS Depression
Observational Study of THC Concentrations in Acute Cannabis-induced CNS Depression
This observational study is being conducted to determine plasma concentrations of tetrahydrocannabinol (THC) and its metabolites, 11-OH-THC and THC-COOH, in plasma of pediatric patients who visit the emergency department due to…
- Trial name
- NCT06017622
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Anebulo Pharmaceuticals
Tuberous Sclerosis Complex (TSC)
Treatment With Full-spectrum Cannabis Extract of Refractory Epilepsy Associated With Tuberous Sclerosis Complex (TSC)
1. To assess treatment efficacy with YCJ-01 by changes in the number of epileptic seizures in patients with refractory epilepsy secondary to Tuberous Sclerosis Complex. 2.
- Trial name
- Spectrum (NCT07403266)
- Testing
- YCJ-01 Full Spectrum cannbis Extract
- Where
- Spain
- Volunteers
- 84 people
- Sponsor
- Oils4Cure
Autistic Disorder
A Trial to Assess the Efficacy and Safety of Medical Grade Cannabis in Children Diagnosed With Autism Spectrum Disorder
This single center, double-blinded, randomized, placebo-controlled crossover trial will assess the efficacy and safety of extraction of cannabis flowers dissolved in olive oil (30% CBD and 1.5% Δ9-THC) vs.
- Trial name
- NCT05413187
- Testing
- Medical Grade Cannabis oil
- Where
- Israel
- Volunteers
- healthy volunteers welcome
- Sponsor
- TO Pharmaceuticals
Autism Spectrum Disorder
Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum Disorder
This is an 18 to 54 week study assessing the efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) on the severity of autism spectrum disorder in young people.
- Trial name
- NCT05626959
- Testing
- NTI164
- Where
- Australia
- Volunteers
- 54 people
- Sponsor
- Fenix Innovation Group
PANS Pediatric Acute-Onset Neuropsychiatric Syndrome
Investigating The Effects Of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) On Paediatric Acute-onset Neuropsychiatric Syndrome (PANS)
This study investigates the effectiveness of a medicinal cannabis extract (NTI164) with 0.08% THC in treating children with pediatric acute-onset neuropsychiatric syndrome (PANS) over a period of 18 to 54 weeks.
- Trial name
- CannaPANS (NCT06621888)
- Testing
- NTI164
- Where
- 2 sites in Australia
- Volunteers
- 18 people
- Sponsor
- Fenix Innovation Group
Chronic Pain, Circulatory Disorders
Cannabis Vs Opioids Pain Management Objective Testing Comparisons
Our purpose for the study is to find safer, less intrusive, better preforming non-addictive products, as an alternative therapy for pain relief and to help alleviate the opioid epidemic ongoing in America today.
- Trial name
- CVO (NCT03734731)
- Testing
- Monochromatic Infrared Photo Energy (MIRE), Transcutaneous Electrical Nerve Stimulation, Opioids
- Volunteers
- 1,000 people
- Sponsor
- American Association of Sensory Electrodiagnostic Medicine
Attention Deficit Hyperactivity Disorder (ADHD)
The Safety and Efficacy of Terpene-enriched Cannabidiol (CBD) Oil in ADHD
ADHD is the most frequent neurodevelopmental disorder in childhood. Symptoms often appear in preschool years, and most children (65-80%) continue to experience some ADHD-associated symptoms into adolescence and adulthood.
- Trial name
- NCT06542445
- Testing
- Oral CBD oil enriched with terpenes
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Bazelet Nehushtan LtD.
Autism Spectrum Disorder
Safety and Efficacy of Oral Full-Spectrum Medicinal Cannabis Plant Extract in Children With Autism Spectrum Disorder.
This is a 20-week open-label study to evaluate the safety and efficacy of full-spectrum medicinal cannabis plant extract < 0.08% THC (FEN164) in children with Autism Spectrum Disorder.
- Trial name
- NCT05516407
- Testing
- FEN164
- Where
- Australia
- Volunteers
- 18 people
- Sponsor
- Fenix Innovation Group